discontinuation often results in weight regain and return of food noise
Hermanns N, Ehrmann D, Schipfer M, Kroger J, Haak T, Kulzer B
Of course, combination comes on top, but if the monotherapy was not competitive, it would be hard to move it into Phase III. The oral GLP-1RA is far from the only obesity drug in AstraZenecas pipeline, said Sharon Barr, executive vice president of BioPharmaceuticals R&D at AstraZeneca
When this equilibrium collapses, misfolded, aggregated, or damaged proteins accumulate, driving organelle dysfunction, maladaptive stress signaling, and disease progression
Impaired glucose metabolism in bipolar patients and response to mood stabilizer treatments
(E) TMAO production induces NLRP3 inflammasome and caspase-1 activity leading to increased inflammation